SMSI +44% . SKUL +33% . ATAI +25% . PLUG +23% . BIG +21% . ZOOM +20% . OHRP +17% . SPRO +17% . THTI +17% . ITMN +15% . Top 10 Losers: NVTL -25% . PXLW -20% . ALSK -17% . ALOG -17% . TACT -14% . DPW -14% . BAXS -14% . NMRX
Market buzz remains high about several pharmaceutical companies' interest in the orphan drug maker. InterMune ( ITMN ) considered selling itself three years ago but no deals were reached due to uncertainty with pirfenidone data. On February 25
NEW YORK, March 7 (Reuters) - InterMune Inc, a drugmaker that specializes in treating fatal scarring of the lungs, is attracting takeover interest from several pharmaceutical companies, according to people familiar with the matter.
Executive summary: You can hold a position in InterMune while strictly limiting your downside risk with a ..... Shares of biotech company InterMune , Inc. ( ITMN ) declined 14.87% Wednesday after having rocketed
of $650M/$300M, not a conservative assumption in our view." Its work here done, Leerink Swan removes its Buy rating on the stock. ITMN is giving back just a bit of yesterday's moonshot , -12.7% to $32.99. Post your comment!
When you do get a biotech investment right, the impacts can be huge on portfolio performance as anyone holding Intermune ( ITMN ) prior to yesterday can attest to. The stock rose 170% Tuesday after Complete Story »
Program, Tuesday February 25. I'm Worried About Tesla ( TSLA ). Other stocks mentioned: Qualcomm ( QCOM ), InterMune ( ITMN ), Priceline ( PCLN ). Cramer is concerned that Tesla ( TSLA ) rallied 14% on an analyst call. A Morgan Stanley
InterMune 's ( ITMN +162.8% ) spectacular gains after reporting ..... analyst Brian Skorney believes, viewing ITMN as an ideal acquisition target for a big ..... of companies with the capability to sell ITMN 's drug with their current salesforce
Top 10 Gainers: ITMN +156% . ZU +42% . HPJ +37% . DARA +30% . LTRX +24% . CBAK +20% . SNSS +18% . OESX +17% . AVID +17% . TSLA +17
as increased sales in the EU," says the team at Summer Street , commenting on the Phase III trial results for InterMune 's ( ITMN +158.4% ) Pirfenidone. "The trial met its primary endpoint, improved force vital capacity (p<0.000001